News
Stay up to date with CellCentric and follow us on Twitter
Key information, updates and news can be found through our tweets
FDA and International Myeloma Society mtg: Instead of prior lines of therapy, it’s useful to assess patients by drug class refractory state.
There is a growing population in multiple myeloma that can benefit from therapeutic options that can be delivered in an outpatient community setting.
We continue to advance our pioneering oral p300/CBP inhibitor in Phase II. Inobrodib gets to the heart of progressing multiple myeloma by impacting MYC and IRF4.
FDA and International Myeloma Society mtg: Instead of prior lines of therapy, it’s useful to assess patients by drug class refractory state.
There is a growing population in multiple myeloma that can benefit from therapeutic options that can be delivered in an outpatient community setting.
We continue to advance our pioneering oral p300/CBP inhibitor in Phase II. Inobrodib gets to the heart of progressing multiple myeloma by impacting MYC and IRF4.
Post advanced therapies, there is a growing need for all oral myeloma treatments. Inobrodib +pom+dex highly effective late/last line (ASH 23) https://lnkd.in/eEZwDAPt
Looking forward to the FDA-IMS meeting. We continue to advance our novel oral drug, inobrodib. Targeting p300/CBP: displacing not degrading. See: https://www.eventcreate.com/e/fda-ims-joint-workshop2024
Great illustration from Blood Cancer Discovery! The power of inobrodib to potentiate IMiDs and treat multiple myeloma via targeting p300/CBP.
FDA and International Myeloma Society mtg: Instead of prior lines of therapy, it’s useful to assess patients by drug class refractory state.
There is a growing population in multiple myeloma that can benefit from therapeutic options that can be delivered in an outpatient community setting.
We continue to advance our pioneering oral p300/CBP inhibitor in Phase II. Inobrodib gets to the heart of progressing multiple myeloma by impacting MYC and IRF4.
Post advanced therapies, there is a growing need for all oral myeloma treatments. Inobrodib +pom+dex highly effective late/last line (ASH 23) https://lnkd.in/eEZwDAPt
Looking forward to the FDA-IMS meeting. We continue to advance our novel oral drug, inobrodib. Targeting p300/CBP: displacing not degrading. See: https://www.eventcreate.com/e/fda-ims-joint-workshop2024
Great illustration from Blood Cancer Discovery! The power of inobrodib to potentiate IMiDs and treat multiple myeloma via targeting p300/CBP.
FDA and International Myeloma Society mtg: Instead of prior lines of therapy, it’s useful to assess patients by drug class refractory state.
There is a growing population in multiple myeloma that can benefit from therapeutic options that can be delivered in an outpatient community setting.
We continue to advance our pioneering oral p300/CBP inhibitor in Phase II. Inobrodib gets to the heart of progressing multiple myeloma by impacting MYC and IRF4.
Post advanced therapies, there is a growing need for all oral myeloma treatments. Inobrodib +pom+dex highly effective late/last line (ASH 23) https://lnkd.in/eEZwDAPt
Looking forward to the FDA-IMS meeting. We continue to advance our novel oral drug, inobrodib. Targeting p300/CBP: displacing not degrading. See: https://www.eventcreate.com/e/fda-ims-joint-workshop2024
Great illustration from Blood Cancer Discovery! The power of inobrodib to potentiate IMiDs and treat multiple myeloma via targeting p300/CBP.
Latest press releases